The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.
Broad-spectrum antiviral compounds that inhibits pyrimidine biosynthesis, triggers innate immunity, and induces antiviral responses.
Small molecule adjuvants that act as vaccine adjuvants by specifically binding to Toll-Like Receptor-8 (TLR8).
The invention provides novel compounds (adjuvants) that can be used as agonists for Toll-Like Receptor 7 (TLR7). By specifically targeting TLR7, these adjuvants elicit a type 1 interferon response which is essential in the development of antiviral responses.
Novel chemical compounds for use as antivirals against VEEV and other alpha viruses.
Using the mutated version of herpes simplex virus-1 (HSV1) to target and terminate CD133+ cancer stem cells.